Ultragenyx Pharmaceutical Inc. (RARE)
Market Cap | 2.69B |
Revenue (ttm) | 590.69M |
Net Income (ttm) | -549.58M |
Shares Out | 94.38M |
EPS (ttm) | -5.88 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,651,300 |
Open | 28.68 |
Previous Close | 28.44 |
Day's Range | 27.88 - 28.80 |
52-Week Range | 25.81 - 60.37 |
Beta | 0.26 |
Analysts | Strong Buy |
Price Target | 86.94 (+205.48%) |
Earnings Date | Aug 5, 2025 |
About RARE
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment... [Read more]
Financial Performance
In 2024, Ultragenyx Pharmaceutical's revenue was $560.23 million, an increase of 29.01% compared to the previous year's $434.25 million. Losses were -$569.18 million, -6.17% less than in 2023.
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for RARE stock is "Strong Buy." The 12-month stock price target is $86.94, which is an increase of 205.48% from the latest price.
News

Ultragenyx to Host Conference Call for Second Quarter 2025 Financial Results and Corporate Update
NOVATO, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for seri...

Ultragenyx: July Selloff Creates Buying Opportunity Ahead Of UX143 Catalyst
Ultragenyx's 35% July selloff is overblown; both UX143 and UX111 programs remain on track with key catalysts ahead. UX143's Phase 3 trial continues for scientific rigor, not due to failure; pivotal da...

Ultragenyx Represents 'Intriguing Buying Opportunity,' Despite Recent Setbacks
HC Wainwright assumed coverage on Ultragenyx Pharmaceuticals, Inc. RARE on Monday, representing an attractive opportunity at current levels.

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NOVATO, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rar...

RARE Investors Have Opportunity to Join Ultragenyx Pharmaceutical Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)---- $RARE--RARE Investors Have Opportunity to Join Ultragenyx Pharmaceutical Inc. Fraud Investigation with the Schall Law Firm.

Ultragenyx Pharmaceutical, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Monday.

US FDA declines to approve Ultragenyx's gene therapy for rare genetic disorder
The U.S. Food and Drug Administration has declined to approve Ultragenyx Pharmaceutical's experimental gene therapy to treat a rare genetic disorder, the company said on Friday.

Ultragenyx Receives Complete Response Letter from FDA for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)
Complete Response Letter (CRL) cited specific chemistry, manufacturing and controls (CMC) related observations that are resolvable

Ultragenyx, Mereo Shares Dive As Brittle Bone Disease Drug Misses Early Win
Ultragenyx Pharmaceutical Inc. RARE and Mereo BioPharma Group plc MREO stocks are plunging on Thursday.

Methode Electronics, Ultragenyx Pharmaceutical And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Thursday.

Ultragenyx and Mereo BioPharma Announce UX143 Phase 3 Orbit Study for Osteogenesis Imperfecta Progressing to Final Analysis
Data from Orbit and Cosmic studies expected around the end of the year Data from Orbit and Cosmic studies expected around the end of the year

Ultragenyx Receives Breakthrough Therapy Designation for GTX-102 in Angelman Syndrome
Phase 3 Aspire study enrollment on track to complete in 2025 Aurora study to evaluate GTX-102 in other Angelman syndrome genotypes and ages expected to initiate later this year NOVATO, Calif., June 27...

Ultragenyx to Participate at Goldman Sachs 46th Annual Global Healthcare Conference
NOVATO, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for ser...

Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report
NOVATO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) released its 2024 Impact Report today, which covers the company's approach to corporate responsibility. T...

Ultragenyx to Participate at Bank of America's 2025 Healthcare Conference
NOVATO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for seri...

Ultragenyx Pharmaceutical Inc. (RARE) Q1 2025 Earnings Call Transcript
Ultragenyx Pharmaceutical Inc. (RARE) Q1 2025 Earnings Call Transcript

Ultragenyx Reports First Quarter 2025 Financial Results and Corporate Update
First quarter total revenue of $139 million, Crysvita® revenue of $103 million and Dojolvi® revenue of $17 million

Ultragenyx to Host Conference Call for First Quarter 2025 Financial Results and Corporate Update
NOVATO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for ser...

Ultragenyx: Commercial Engine Fuels Rare Disease Pipeline
Ultragenyx shows strong revenue growth and disciplined expense management, making it a compelling long-term investment despite inherent biotechnology risks. The company's diverse revenue streams from ...

Ultragenyx to Participate at Investor Conferences in March
NOVATO, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for ser...

Ultragenyx Pharmaceutical Inc. (RARE) Q4 2024 Earnings Call Transcript
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q4 2024 Earnings Conference Call February 13, 2025 5:00 PM ET Company Participants Joshua Higa - VP, IR Emil Kakkis - CEO and President Erik Harris - CCO ...

Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Update
2024 Total Revenue of $560 million, exceeding guidance Crysvita® revenue of $410 million and Dojolvi® revenue of $88 million

Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update
NOVATO, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for seri...

Ultragenyx Announces New Data Demonstrating that Treatment with UX111 AAV Gene Therapy Significantly Improved Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome Type A (MPS IIIA) Correlated with Sustained Reductions in CSF-HS
Modified intent-to-treat group demonstrated +22.7 point (p

Ultragenyx's Multiple Commercial Assets And Candidates Impress Analyst; Sees Solid Upside
In conjunction with the 2025 J.P. Morgan Healthcare Conference, the analyst hosted an investor lunch with Ultragenyx Pharmaceutical Inc RARE.